文献速递药疹与重症皮肤不良反应

APOA4作为Stevens-Johnson综合征/中毒性表皮坏死松解症预后新预测因子:两项前瞻性队列的蛋白质组学分析

APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts.
PubMed 文献 · J Am Acad Dermatol · 2023-03-22

研究比较阿达木单抗联合糖皮质激素与单用糖皮质激素治疗SJS/TEN的疗效与安全性,并做血浆蛋白质组学分析。联合治疗显著缩短黏膜皮肤再上皮化和愈合时间,减少糖皮质激素副作用。APOA4是最显著的差异表达蛋白之一,多因素回归显示APOA4水平与SJS/TEN预后参数显著相关(P = .004),但与SCORTEN评分无显著相关(P = .118)。

要点

  • 阿达木单抗联合糖皮质激素较单用糖皮质激素显著缩短SJS/TEN黏膜皮肤再上皮化及愈合时间。
  • 联合治疗减少糖皮质激素引起的副作用。
  • APOA4水平与SJS/TEN预后参数显著相关(P = .004),或可作为新型预后标志物。

核心结论

  • 阿达木单抗联合糖皮质激素在SJS/TEN患者中较单用糖皮质激素显示出显著临床获益。
  • APOA4可能作为SJS/TEN的新型预后标志物。

研究设计与样本

  • 比较两个SJS/TEN患者治疗队列,评估阿达木单抗联合治疗的疗效与安全性。
  • 收集患者血浆样本进行蛋白质组学分析。

主要发现

  • 阿达木单抗联合治疗显著缩短黏膜皮肤再上皮化和愈合时间,并减少糖皮质激素引起的副作用。
  • 血浆蛋白质组学显示载脂蛋白A-IV(APOA4)是最显著的差异表达蛋白之一。
  • 多因素回归分析显示APOA4水平与SJS/TEN预后参数显著相关(P = .004),但与疾病严重程度评分SCORTEN无显著相关(P = .118)。

关键数值与推荐

  • APOA4水平与SJS/TEN预后参数显著相关(P = .004),与SCORTEN评分无显著相关(P = .118)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 队列规模相对较小。
  • 两个队列的总体SCORTEN评分均较低。
  • 需进一步研究以有效将APOA4纳入当前SCORTEN驱动的方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening adverse drug reactions. Conventional systemic therapies are of limited efficacy and often exhibit strong side effects. OBJECTIVE: To assess the efficacy and safety of the combination treatment with a tumor necrosis factor-α antagonist adalimumab and delineate the underlying mechanisms. METHODS: We evaluated the efficacy and safety of the combination therapy with adalimumab by comparing 2 treatment cohorts of SJS/TEN patients. Patient plasma samples were collected for proteomics analysis. RESULTS: The combination therapy with adalimumab significantly shortened the time to mucocutaneous re-epithelization and healing, with reduced side effects caused by corticosteroids. Plasma proteomic profiling showed that apolipoprotein A-IV (APOA4) was one of the most significant differentially expressed proteins. Multivariate regression analysis revealed that APOA4 level was significantly associated with prognosis parameter of SJS/TEN (P = .004), but not with disease severity score (severity-of-illness score for toxic epidermal necrolysis [SCORTEN]) (P = .118). Thus further research will be helpful to effectively incorporate APOA4 into current SCORTEN-driven protocols. LIMITATIONS: The cohort size is relatively small. Both cohorts had low overall SCORTEN scores. CONCLUSION: Adalimumab in combination with corticosteroids demonstrates significant clinical benefits over corticosteroids alone in SJS/TEN patients. Moreover, APOA4 may serve as a novel prognostic marker of SJS/TEN.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gong T, Zhang P, Ruan SF, et al. APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: A proteomics analysis from two prospective cohorts. J Am Acad Dermatol. 2023. PMID: 36963506. doi:10.1016/j.jaad.2023.02.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。